Seema Gupta

Title: Seema Gupta: Innovator in Immune Therapy Resistance

Introduction

Seema Gupta is a prominent inventor based in Bethesda, MD (US). She has made significant contributions to the field of immunotherapy, particularly in addressing resistance to anti-PD1 therapy. Her innovative work has the potential to enhance treatment outcomes for patients undergoing immune therapy.

Latest Patents

Seema Gupta holds a patent titled "Methods for detecting and reversing immune therapy resistance." This patent provides compositions and methods for detecting and treating resistance to anti-PD1 therapy. The invention includes compositions that specifically bind and deplete dysfunctional T cells, such as CD38PD-1T cells and CD38CD8T-cells. The methods involve administering antibodies or fusion proteins that promote the depletion of these dysfunctional T cells. Additionally, the patent outlines a method for detecting and treating anti-PD1 therapy resistance by measuring the levels of CD38+PD1+CD8 T cells in blood or tissue samples prior to therapy.

Career Highlights

Seema Gupta is affiliated with the Augusta University Research Institute, Inc., where she continues to advance her research in immunotherapy. Her work is characterized by a commitment to improving therapeutic strategies for patients facing challenges with immune resistance.

Collaborations

Seema has collaborated with notable colleagues, including Samir N Khleif and Vivek Verma, who share her dedication to advancing the field of immunotherapy.

Conclusion

Seema Gupta's innovative contributions to the detection and treatment of immune therapy resistance highlight her role as a leading inventor in the field. Her work promises to make a significant impact on the future of cancer treatment.